WebApr 7, 2024 · Target values for the price of one SCYNEXIS share for May 2025. The weighted average target price per SCYNEXIS share in May 2025 is: 1.40. In May, the Positive dynamics for Momo shares will prevail with possible monthly volatility of 16.287% volatility is expected. Pessimistic target level: 1.32. Optimistic target level: 1.57. WebMar 31, 2024 · Net loss for the full year 2024, was $62.8 million, or $1.47 per share, compared to net loss of $32.9 million, or $1.25 per share for the comparable prior year. Cash Balance. Cash, cash equivalents and short-term investments totaled $73.5 million on December 31, 2024, compared to $104.5 million in cash and cash equivalents on …
Michael Burry dumped just about everything in Q3 to guard …
WebCurrent and historical return on equity (ROE) values for SCYNEXIS (SCYX) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have … WebMar 31, 2024 · Shares of Scynexis SCYX surged almost 76% on Mar 30, after it entered an exclusive license agreement with GSK Plc GSK to commercialize Brexafemme (ibrexafungerp), an antifungal treatment for ... mark brelsford motorcycle racer
四川省继续医学教育网
WebApr 21, 2024 · SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotech company pioneering innovative medicines to overcome & prevent difficult-to-treat & drug-resistant fungal infections. WebAug 21, 2024 · Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results. WebMar 21, 2024 · Scynexis price target raised to $9 from $8 at Guggenheim. 03/31/23 Cantor Fitzgerald. 'Lots to like' about Scynexis post-Q4, GSK deal, says Cantor Fitzgerald. 03/30/23 Maxim. Scynexis price target raised to $10 from $7 at Maxim. 03/21/23 Cantor Fitzgerald. Cantor reiterates Overweight ratings on anti-fungal stocks Cidara, Scynexis. mark bremner aberdeen city council